Vincent Pons1, Pascal Lévesque1, Marie-Michèle Plante1, Serge Rivest2. 1. Neuroscience laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier boulevard, Québec City, QC, G1V 4G2, Canada. 2. Neuroscience laboratory, CHU de Québec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier boulevard, Québec City, QC, G1V 4G2, Canada. serge.rivest@crchudequebec.ulaval.ca.
Abstract
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia in the world. Microglia are the innate immune cells of CNS; their proliferation, activation, and survival in pathologic and healthy brain have previously been shown to be highly dependent on CSF1R. METHODS: Here, we investigate the impact of such receptor on AD etiology and microglia. We deleted CSF1R using Cre/Lox system; the knockout (KO) is restricted to microglia in the APP/PS1 mouse model. We induced the knockout at 3 months old, before plaque formation, and evaluated both 6- and 8-month-old groups of mice. RESULTS: Our findings demonstrated that CSF1R KO did not impair microglial survival and proliferation at 6 and 8 months of age in APP cKO compared to their littermate-control groups APPSwe/PS1. We have also shown that cognitive decline is delayed in CSF1R-deleted mice. Ameliorations of AD etiology are associated with a decrease in plaque volume in the cortex and hippocampus area. A compensating system seems to take place following the knockout, since TREM2/β-Catenin and IL-34 expression are significantly increased. Such a compensatory mechanism may promote microglial survival and phagocytosis of Aβ in the brain. CONCLUSIONS: Our results provide new insights on the role of CSF1R in microglia and how it interacts with the TREM2/β-Catenin and IL-34 system to clear Aβ and ameliorates the physiopathology of AD.
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia in the world. Microglia are the innate immune cells of CNS; their proliferation, activation, and survival in pathologic and healthy brain have previously been shown to be highly dependent on CSF1R. METHODS: Here, we investigate the impact of such receptor on AD etiology and microglia. We deleted CSF1R using Cre/Lox system; the knockout (KO) is restricted to microglia in the APP/PS1 mouse model. We induced the knockout at 3 months old, before plaque formation, and evaluated both 6- and 8-month-old groups of mice. RESULTS: Our findings demonstrated that CSF1R KO did not impair microglial survival and proliferation at 6 and 8 months of age in APP cKO compared to their littermate-control groups APPSwe/PS1. We have also shown that cognitive decline is delayed in CSF1R-deleted mice. Ameliorations of AD etiology are associated with a decrease in plaque volume in the cortex and hippocampus area. A compensating system seems to take place following the knockout, since TREM2/β-Catenin and IL-34 expression are significantly increased. Such a compensatory mechanism may promote microglial survival and phagocytosis of Aβ in the brain. CONCLUSIONS: Our results provide new insights on the role of CSF1R in microglia and how it interacts with the TREM2/β-Catenin and IL-34 system to clear Aβ and ameliorates the physiopathology of AD.
Authors: Jean-Philippe Michaud; Maxime Hallé; Antoine Lampron; Peter Thériault; Paul Préfontaine; Mohammed Filali; Pascale Tribout-Jover; Anne-Marie Lanteigne; Rachel Jodoin; Christopher Cluff; Vincent Brichard; Rémi Palmantier; Anthony Pilorget; Daniel Larocque; Serge Rivest Journal: Proc Natl Acad Sci U S A Date: 2013-01-15 Impact factor: 11.205
Authors: Karel Otero; Isaiah R Turnbull; Pietro Luigi Poliani; William Vermi; Elisa Cerutti; Taiki Aoshi; Ilaria Tassi; Toshiyuki Takai; Samuel L Stanley; Mark Miller; Andrey S Shaw; Marco Colonna Journal: Nat Immunol Date: 2009-06-07 Impact factor: 25.606
Authors: Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray Journal: Nat Med Date: 2007-10-14 Impact factor: 53.440
Authors: Kristin A Sauter; Clare Pridans; Anuj Sehgal; Yi Ting Tsai; Barry M Bradford; Sobia Raza; Lindsey Moffat; Deborah J Gow; Philippa M Beard; Neil A Mabbott; Lee B Smith; David A Hume Journal: J Leukoc Biol Date: 2014-03-20 Impact factor: 4.962
Authors: Raquel Sanchez-Varo; Marina Mejias-Ortega; Juan Jose Fernandez-Valenzuela; Cristina Nuñez-Diaz; Laura Caceres-Palomo; Laura Vegas-Gomez; Elisabeth Sanchez-Mejias; Laura Trujillo-Estrada; Juan Antonio Garcia-Leon; Ines Moreno-Gonzalez; Marisa Vizuete; Javier Vitorica; David Baglietto-Vargas; Antonia Gutierrez Journal: Int J Mol Sci Date: 2022-05-12 Impact factor: 6.208
Authors: Katiria Soto-Diaz; Mario Vailati-Riboni; Allison Y Louie; Daniel B McKim; H Rex Gaskins; Rodney W Johnson; Andrew J Steelman Journal: Front Immunol Date: 2021-11-26 Impact factor: 7.561